Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11797MR)

This product GTTS-WQ11797MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Breast Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancers (NSCLC), Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11797MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14482MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ9439MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ9921MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ9827MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ10500MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ14972MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ14739MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ12398MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW